Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Hey! Dildos Sale in our Dildos Store!
Popular Articles

Needle Exchange Program In Humboldt County, Calif., Forced To End; Officials Hoping For Federal Help
Health officials in Humboldt County, Calif., "will be watching closely" the debate expected to ensue over legislation introduced last week containing "a provision that would scrap the federal funding ban on needle exchange programs that has been in place for years," the Eureka Times-Standard reports. According to the Times-Standard, "This month, Open Door Community Health Centers" clinics in Arcata and Eureka quietly stopped administering the needle exchange program they have operated for almost a decade." Open Door Community Health Centers Chief Operating Officer Cheyenne Spetzler, said, "The footprint of the program just kept getting bigger." In addition, grant funding was often limited to covering the costs of the needles and not the costs of administering the programs, Spetzler said. County Department of Health and Human Services Programs Director Barbara LaHaie said the county is currently seeking alternatives to continue the program. However, "Without a reliable funding stream, that may prove difficult," the article states (Greenson, 7/13).
drugs without prescription
Transdel Pharmaceuticals Provides Update On Timing Of Results For Phase 3 Study
Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) a specialty pharmaceutical company focused on developing non-invasive, topically administered products, announced that they anticipate reporting top-line results from their current Phase 3 study of Ketotransdel(R) during the third quarter of 2009.
News of the day
The Government Of Canada Reaches Another Important Milestone With The Chemicals Management Plan
The Honourable Leona Aglukkaq, Minister of Health, and the Honourable Jim Prentice, Canada"s Environment Minister, today announced the release of the draft screening assessments and risk management scope documents for 18 substances assessed in Batch 6 of the Chemicals Management Plan. The Government has reached the halfway point in its commitment to assess approximately 200 high-priority substances as part of the Chemicals Management Plan.
Cardiovascular

Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial

Stem Cell Therapeutics Corp. ("SCT" or "the Company") (TSX VENTURE:SSS) is pleased to announce the U.S. Food and Drug Administration ("FDA") has provided a verbal confirmation to remove its clinical hold placed on NTx®-265 on September 18, 2008. This will allow SCT to commence the recruitment of patients under an amended protocol using NTx®-265 for the Company"s Phase IIb clinical trial treating acute ischemic stroke. Dr. Alan Moore, President and CEO, commented as follows: "We are very pleased that our series of collaborative meetings with the FDA has resulted in this positive development. We are expecting to receive written notification from the FDA in the near future following which we will finalize the plans for our stroke trial. We will issue another press release once this has been determined." About REGENESIS NTx®-265 is SCT"s lead therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin ("hCG") and Erythropoietin ("EPO"), targeting the treatment of stroke. The twin objectives of the treatment are to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke, and importantly, to direct motor, visual, and cognitive recovery after the acute ischemic stroke. Encouraging clinical results from SCT"s BETAS Phase IIa stroke trial were presented at the International Stroke Conference in February 2009, showing clinically relevant recovery in 12 of 12 patients who received the complete treatment. Stem Cell Therapeutics Corp.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009